{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:35:06Z","timestamp":1793453706589,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117775","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:11:22Z","timestamp":1791558682000},"page":"117775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["First-line fluoropyrimidine- versus gemcitabine-based chemotherapy for metastatic recurrence after resection of ampullary adenocarcinoma: A real-world analysis of the FFCD-AC cohort"],"prefix":"10.1016","volume":"248","author":[{"given":"Erwan","family":"Vo-Quang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-6448","authenticated-orcid":false,"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3743","authenticated-orcid":false,"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-8525","authenticated-orcid":false,"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Truant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-4830","authenticated-orcid":false,"given":"Anna","family":"Pellat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Amil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7502-7708","authenticated-orcid":false,"given":"Marine","family":"Jary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7530-4621","authenticated-orcid":false,"given":"Sylvain","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Guillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2802-4974","authenticated-orcid":false,"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2026.117775_bib1","article-title":"The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma","volume":"9","author":"Zimmermann","year":"2019","journal-title":"Sci Rep 3"},{"key":"10.1016\/j.ejca.2026.117775_bib2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2407-8-170","article-title":"Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma","volume":"8","author":"Westgaard","year":"2008","journal-title":"BMC Cancer 11 juin"},{"key":"10.1016\/j.ejca.2026.117775_bib3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/1471-2407-13-428","article-title":"Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin","volume":"13","author":"Bronsert","year":"2013","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.117775_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jamcollsurg.2008.01.028","article-title":"Tumors of the ampulla of vater: histopathologic classification and predictors of survival","volume":"207","author":"Carter","year":"2008","journal-title":"J Am Coll Surg ao\u00fbt"},{"issue":"12","key":"10.1016\/j.ejca.2026.117775_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103988","article-title":"A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort","volume":"9","author":"Roth","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ejca.2026.117775_bib6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamasurg.2019.1170","article-title":"Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma","volume":"154","author":"Ecker","year":"2019","journal-title":"JAMA Surg 1 ao\u00fbt"},{"issue":"5","key":"10.1016\/j.ejca.2026.117775_bib7","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1111\/ajco.12612","article-title":"Role of adjuvant chemotherapy in T2N0M0 periampullary cancers","volume":"13","author":"Ostwal","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117775_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"Jama 11 juill"},{"issue":"7","key":"10.1016\/j.ejca.2026.117775_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.6004\/jnccn.2023.0034","article-title":"Ampullary adenocarcinoma, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Chiorean","year":"2023","journal-title":"J Natl Compr Canc Netw juill"},{"issue":"9","key":"10.1016\/j.ejca.2026.117775_bib10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.dld.2024.04.027","article-title":"Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR)","volume":"56","author":"Hautefeuille","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"16","key":"10.1016\/j.ejca.2026.117775_bib11","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","volume":"27","author":"Overman","year":"2009","journal-title":"J Clin Oncol 1 juin"},{"issue":"9","key":"10.1016\/j.ejca.2026.117775_bib12","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/annonc\/mdt191","article-title":"A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy","volume":"24","author":"Jiang","year":"2013","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2026.117775_bib13","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med 12 mai"},{"issue":"3","key":"10.1016\/j.ejca.2026.117775_bib14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study","volume":"40","author":"Phelip","year":"2022","journal-title":"J Clin Oncol 20 janv"},{"issue":"18","key":"10.1016\/j.ejca.2026.117775_bib15","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2026.117775_bib16","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdq038","article-title":"Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study","volume":"21","author":"Zaanan","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117775_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol F\u00e9vr"},{"issue":"11","key":"10.1016\/j.ejca.2026.117775_bib18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117775_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pan.2019.01.019","article-title":"Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy","volume":"19","author":"Bowitz Lothe","year":"2019","journal-title":"Pancreatol mars"},{"issue":"4","key":"10.1016\/j.ejca.2026.117775_bib20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s12032-009-9351-4","article-title":"The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater","volume":"27","author":"Kim","year":"2010","journal-title":"Med Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.117775_bib21","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid ao\u00fbt"},{"issue":"2","key":"10.1016\/j.ejca.2026.117775_bib22","article-title":"Advanced ampullary cancer: post-hoc analysis of the ABC-01, ABC-02, and ABC-03 clinical trials","volume":"31","author":"Lamarca","year":"2026","journal-title":"Oncol 17 janv"},{"issue":"1","key":"10.1016\/j.ejca.2026.117775_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamasurg.2016.3466","article-title":"Association of histopathologic phenotype of periampullary adenocarcinomas with survival","volume":"152","author":"Williams","year":"2017","journal-title":"JAMA Surg 1 janv"},{"issue":"2","key":"10.1016\/j.ejca.2026.117775_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","article-title":"Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma","volume":"29","author":"Yachida","year":"2016","journal-title":"Cancer Cell 8 F\u00e9vr"},{"issue":"4","key":"10.1016\/j.ejca.2026.117775_bib25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.celrep.2015.12.005","article-title":"Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation","volume":"14","author":"Gingras","year":"2016","journal-title":"Cell Rep 2 F\u00e9vr"},{"issue":"5","key":"10.1016\/j.ejca.2026.117775_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104480","article-title":"Genomic profiling unlocks new treatment opportunities for ampullary carcinoma","volume":"10","author":"Fabregat-Franco","year":"2025","journal-title":"ESMO Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:18:04Z","timestamp":1793452684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926015571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":26,"alternative-id":["S0959804926015571"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117775","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line fluoropyrimidine- versus gemcitabine-based chemotherapy for metastatic recurrence after resection of ampullary adenocarcinoma: A real-world analysis of the FFCD-AC cohort","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117775"}}